MedTrace Logo

Real-world Daptomycin Use in Chinese ICUs

NCT03588637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-07-25

No results posted yet for this study

Summary

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Conditions

  • Daptomycin
  • Real-world Study
  • Intensive Care Unit

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-01-01
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03588637 on ClinicalTrials.gov